Oruka Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Oruka Therapeutics, Inc. (ORKA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $877.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-10
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $25.00K.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $214.00K.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.41M.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $84.00K, a 82.89% decline from fiscal 2020.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $491.00K, a 427.96% increase from fiscal 2019.
- Oruka Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $93.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 5 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 8 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 11 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $877.00K 10-Q · filed 2026-08-10 | ||||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $25.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.41M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.41M 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | $1.39M 10-Q · filed 2026-08-10 | ||||||
| 2024-12-31 | $982.00K 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | $982.00K 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $982.00K 10-Q · filed 2025-08-11 | $214.00K 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $214.00K 10-Q · filed 2024-04-25 | ||||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $84.00K 10-K · filed 2023-02-24 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $84.00K 10-Q · filed 2022-10-28 | |||||
| 2021-06-30 | $84.00K 10-Q · filed 2022-08-02 | ||||||
| 2020-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $442.00K derived: sum of 2 quarters · filed 2022-03-14 | $442.00K derived: sum of 3 quarters · filed 2022-03-14 | $491.00K 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 derived: sum of 2 quarters · filed 2021-11-02 | $49.00K 10-Q · filed 2021-11-02 | $82.00K derived: sum of 4 quarters · filed 2021-11-02 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $49.00K 10-Q · filed 2021-08-04 | $82.00K derived: sum of 3 quarters · filed 2021-08-04 | $82.00K derived: sum of 4 quarters · filed 2021-08-04 | |||
| 2020-03-31 | $49.00K 10-Q · filed 2021-05-11 | $82.00K derived: sum of 2 quarters · filed 2021-05-11 | $82.00K derived: sum of 3 quarters · filed 2021-05-11 | $82.00K derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $33.00K derived: sum of 2 quarters · filed 2021-03-18 | $33.00K derived: sum of 3 quarters · filed 2021-03-18 | $93.00K 10-K · filed 2021-03-18 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $0.00 derived: sum of 2 quarters · filed 2020-11-02 | $60.00K 10-Q · filed 2020-11-02 | ||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $60.00K 10-Q · filed 2020-08-05 | |||||
| 2019-03-31 | $60.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |